1148000-14-9

Basic information

• Product Name: 2-(3-(2,6-dichlorophenoxy)propyl)isoindoline-1,3-dione
• Synonyms: 2-(3-(2,6-dichlorophenoxy)propyl)isoindoline-1,3-dione
• CAS NO: 1148000-14-9
• Molecular Weight: 350.201
• Mol File: 1148000-14-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(3-(2,6-dichlorophenoxy)propyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-(2,6-dichlorophenoxy)propyl)isoindoline-1,3-dione(1148000-14-9)
• EPA Substance Registry System: 2-(3-(2,6-dichlorophenoxy)propyl)isoindoline-1,3-dione(1148000-14-9)

Safety Data

• Hazardous Substances Data: 1148000-14-9(Hazardous Substances Data)

Usage

Chemical class

isoindoline-1,3-dione derivatives

Core structure

isoindoline-1,3-dione

Substituent group

2-(3-(2,6-dichlorophenoxy)propyl)

Potential applications

pharmaceuticals, organic synthesis, material science

Functional group

2,6-dichlorophenoxy (potentially useful for herbicidal and pesticidal applications)

Biological activity

potential DNA-binding agent and antitumor agent (of interest for medicinal chemistry research)

Industrial and scientific applications

possible due to its various potential uses.

Upstream product

• 87-65-0 2,6-Dichlorophenol 
• 5460-29-7 2-(3-bromopropyl)isoindole-1,3-dione 

Downstream Products

• 57465-87-9 3-(2,6-dichlorophenoxy)propan-1-amine 

Relevant articles and documents

Discovery of N-Aryloxypropylbenzylamines as Voltage-Gated Sodium Channel NaV1.2-Subtype-Selective Inhibitors

We previously reported that a lipophilic N-(4′-hydroxy-3′,5′-di-tert-butylbenzyl) derivative (1) of the voltage-gated sodium channel blocker mexiletine, was a more potent sodium channel blocker in vitro and in vivo. We demonstrate that replacing the chiral methylethylene linker between the amine and di-tert-butylphenol with an achiral 1,3-propylene linker (to give (2)) maintains potency in vitro. We synthesized 25 analogues bearing the 1,3-propylene linker and found that minor structural changes resulted in pronounced changes in state dependence of blocking human NaV1.2 and 1.6 channels by high-throughput patch-clamp analysis. Compared to mexiletine, compounds 1 and 2 are highly selective NaV1.2 inhibitors and >500 times less potent in inhibiting NaV1.6 channels. On the other hand, a derivative (compound 4) bearing 2,6-dimethoxy groups in place of the 2,6-dimethyl groups found in mexiletine was found to be the most potent inhibitor, but is nonselective against both channels in the tonic, frequency-dependent and inactivated states. In a kindled mouse model of refractory epilepsy, compound 2 inhibited seizures induced by 6 Hz 44 mA electrical stimulation with an IC50 value of 49.9±1.6 mg kg?1. As established sodium channel blockers do not suppress seizures in this mouse model, this indicates that 2 could be a promising candidate for treating pharmaco-resistant epilepsy.

PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS

The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellul